ArticleClinical and molecular hepatology2026

Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study".

Shio-Shin Jean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.